Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2203)	1/29/2008 2:21:31 PM
From: Jibacoa	Respond to of 3722

Well, LMRA has been up 61.13% & still is up 50.22% at present with volume now >3M It is still having some good upticks, with its nearest intraday support now at $3.24 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2203)	1/30/2008 4:59:26 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Well, LMRA released today some good news on its subsidiary Plexera, but the stock was down 8.52% on volume of 1,529,358 about 5x its ADV. The volume was < yesterday's. The profit taking dipped the stock again below the $3 level, but didn't close yesterday's UG & it seems it is trying to get above $3 AHs in spite of the general market's bad performance in the last half hour before the close. bigcharts.marketwatch.com LMRA announced today an option agreement with Auguron Biosciences, giving them rights to exclusive access to use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA) technology on the Plexera Kx Array Platform. The NAPPA technology was developed at the Harvard Institute of Proteomics and is protected by several issued and pending patents, licensed exclusively to Auguron Biosciences. The technology enables fresh, functional proteins to be generated on high density microchips from surface printed DNA. “Plexera’s business model is focused on developing high value content consumables,” said Dr. Joe Vallner, Plexera Chairman and Chief Executive Officer. “We believe Auguron’s NAPPA technology will allow us to offer a unique and compelling assortment of high quality and unique content to both the life science and pharmaceutical markets giving us a significant competitive advantage and becoming a cornerstone of our content development.” Auguron was formed in early 2007 to commercialize developments at the Harvard Institute for Proteomics (HIP). “Empowering Plexera’s label-free Kx Array platform with NAPPA will provide access to a virtually unlimited source of protein content with very high levels of control over both composition and functionality,” said Jim Richey, Co-Founder and Chief Executive of Auguron. “By printing DNA and expressing proteins in-situ, NAPPA skips the expense, time, yield and activity consuming steps associated with conventional printed protein arrays. Combining Plexera’s ability to interrogate interactions of every array element simultaneously, without the use of labels, presents previously unimagined investigative opportunities for complex biological systems.” While conventional label-free platforms look at one or several spots at a time, Plexera’s platform is designed to monitor thousands of elements simultaneously. “It is this capability combined with NAPPA’s power to access every gene in the genome that makes this combination so compelling,” Richey continued. The Agreement provides Plexera exclusive access for a one year period with terms for a one year extension. Plexera will test and develop NAPPA as a content source for Kx in collaboration together with Auguron and other strategic partners. At any time during the period, Plexera may exercise the option to negotiate an exclusive license to NAPPA within the field of detection by or depending upon SPR, the label free detection method used in the Kx Array platform. The financial details were not disclosed, the companies have stated that the fundamental terms of the license are pre-agreed in the option. If Plexera exercises the option, the companies envision a strategic relationship where Auguron produces and supplies NAPPA enabled microchips to Plexera. Dr. Vallner also said: “The internal development teams alongside our external partners are focused and on track to launch the Kx5 biosensor instrument in May, 2008 to the therapeutic antibody development market. This option agreement announced today provides us with the protection we need to fully investigate and develop NAPPA and Kx into an integrated solution that will broaden our product offering to provide unique solutions to drug and vaccine discovery and development and basic research.” I will keep my target at $5.<g> bigcharts.marketwatch.com Bernard